MARK CALDERWOOD, MD
Ophthalmology Physician in HAMILTON, Montana. CMS National Plan and Provider Enumeration System profile including specialty classification, practice address, and Medicare prescribing data when reported.
What stands out: MARK CALDERWOOD, MD filed 520 Medicare Part D claims in 2023 across HAMILTON, Montana. Every figure on this page comes straight from federal CMS records, with no proprietary rating applied.
MARK CALDERWOOD, MD practices in an ABMS-board-eligible specialty but we don't have enough CMS-participation signals to confirm active board-certified status. Consult CertificationMatters.org (the official ABMS public lookup).
MARK CALDERWOOD, MD at a glance
Quality data not reportedPrimary specialty
Medicare Part D claims
Specialty distribution in Montana
How Ophthalmology Physician compares to other specialties among Montana providers
Ophthalmology Physician share within Montana
Ophthalmology Physician is one of the more visible NUCC categories in Montana
Each bar reflects the share of in-state providers whose primary NUCC taxonomy matches the specialty. Long tail of ~690 NUCC codes folded into "Other" to keep the comparison legible.
Specialty board-certification context
Estimated specialty board-certified rate — Ophthalmology Physician (ABMS / AOA reference)
- Est. board-certified rate
- 78%
- Ophthalmology Physician ABMS/AOA estimate
Est. board-certified rate (Ophthalmology Physician) — ABMS / AOA estimate
Verify credentials
- Verify via ABMS free public lookup
- Verify via AOA osteopathic boards
- Specialty volume Ophthalmology Physician US NPIs
Specialty board-certified rate — Ophthalmology Physician estimate
Board certification through an ABMS or AOA member board signals voluntary post-licensure examination plus Maintenance of Certification cycles. CMS does not publish a per-provider board-certification field; the figure shown is the specialty-level estimated rate from ABMS / AOA reference data.
The Merit-based Incentive Payment System (MIPS) scores providers 0–100 across four performance categories: Quality, Cost, Promoting Interoperability, and Improvement Activities, weighted under 42 CFR §414.1380. Reporting is voluntary for many small practices, so absence of a MIPS score is not a quality signal.
Board certification through an ABMS or AOA member board signals voluntary post-licensure examination plus continuous Maintenance of Certification cycles. Verify any individual provider's status through certificationmatters.org (ABMS) or osteopathic.org (AOA).
MARK CALDERWOOD, MD is a Ophthalmology Physician provider practicing in HAMILTON, Montana, according to the CMS National Plan and Provider Enumeration System (NPPES). Credentials: MD. NPI: 1447353024. This profile includes practice location, specialty classification, and organizational affiliations from the CMS provider registry. Provider information is self-reported to CMS and updated monthly.
MARK CALDERWOOD, MD appears in the CMS NPPES registry as a Ophthalmology Physician provider holding MD credentials at 300 N 10TH ST STE A, HAMILTON, MT, 59840, with a listed phone of (406) 363-5434. NPI 1447353024 was issued on 09/07/2006. Because NPPES data is self-reported by the provider and refreshed monthly, the address, phone, and specialty reflect what CALDERWOOD most recently submitted to CMS rather than a vetted directory listing, which is why patients should always confirm the practice is still at this location before scheduling.
Medicare Part D records for calendar year 2023 show 520 prescription claims written by this provider, covering 122 Medicare beneficiaries and totaling roughly $112K in drug spend, split 52% brand-name and 48% generic by claim count. These figures capture only Medicare Part D — commercial insurance, Medicaid, and cash-pay prescriptions are not included, and any drug-beneficiary cell under 11 is suppressed by CMS for patient privacy.
Ophthalmology Physician is a mid-sized specialty nationwide, with 22,090 enrolled providers across 56 states and an average of 1,420 Part D claims per prescriber, so the context for interpreting these metrics differs meaningfully from a primary-care baseline. Important: PlainDoctor is a directory of publicly available government data, not medical advice, a malpractice database, or a quality rating. Inclusion here does not imply a recommendation, and absence of complaints or sanctions on this page does not mean none exist — always verify credentials through the NPPES NPI Registry, your state medical board, and the ABMS or AOA before making healthcare decisions.
Practice Address
Provider Details
| NPI | 1447353024 |
|---|---|
| Specialty | Ophthalmology Physician |
| Credentials | MD |
| Gender | Male |
| NPI Issued | 09/07/2006 |
Verify this provider's license
PlainDoctor pulls this profile from the CMS NPPES public registry. Confirm MARK CALDERWOOD, MD's current license status, disciplinary history, and board certifications with the Montana Board of Medical Examiners in Montana before relying on this page for a clinical or care decision.
How we sourced this profile
Brand vs generic prescribing mix · Brand-heavy
52% brand-name claims vs 48% generic, on 520 2023 Medicare Part D claims.
The federal Medicare Part D Generic Dispensing Rate national benchmark sits near 90% generic / 10% brand for primary-care prescribers, per CMS Office of the Actuary 2024 estimates. Higher brand share is common in specialty prescribing where generic equivalents are not available.
Medicare Part D Prescribing Data
CMS Medicare Part D prescriber-level data for calendar year 2023.
Prescribing Breakdown
- 30-Day Fills
- 801
- Total Day Supply
- 21,323
- Brand vs Generic
- 52% brand / 48% generic
- Brand Drug Cost
- $106K
- Generic Drug Cost
- $6K
Patient Demographics
- Average Patient Age
- 78.5 years
- Avg HCC Risk Score
- 1.03
- Gender Split
- 70% female / 30% male
Top Prescribed Drugs (Medicare Part D)
Top drugs by claim count for calendar year 2023. Based on Medicare Part D data only.
| Drug | Claims |
|---|---|
| Latanoprost | 203 |
| Restasis Cyclosporine | 93 |
| Timolol Maleate | 55 |
| Neomycin-Polymyxin-Dexameth Neomycin/Polymyxin B/Dexametha | 53 |
| Cyclosporine | 18 |
| Erythromycin Erythromycin Base | 16 |
| Dorzolamide-Timolol Dorzolamide Hcl/Timolol Maleat | 11 |
* Counts below 11 are suppressed by CMS for patient privacy. Generic names shown where available from CMS Part D data.
Ophthalmology Physician Overview
How MARK CALDERWOOD, MD fits within the Ophthalmology Physician landscape nationally.
MARK CALDERWOOD, MD's 520 claims are below the specialty average of 1,420.
Nearby Ophthalmology Physician Providers in Montana
Other clinicians with the same primary specialty enrolled in Montana, drawn from the same CMS NPPES roster as CALDERWOOD.
Compare Ophthalmology Physician nationally: see state-by-state distribution →
Healthcare Guides
Learn more about finding, verifying, and understanding healthcare providers.
Explore Montana
Frequently Asked Questions
What is MARK CALDERWOOD, MD's specialty? ▼
How much does MARK CALDERWOOD, MD prescribe under Medicare Part D? ▼
Where is MARK CALDERWOOD, MD located? ▼
What is MARK CALDERWOOD, MD's NPI number? ▼
Does MARK CALDERWOOD, MD prescribe more brand-name or generic drugs? ▼
How many Ophthalmology Physician providers are there in the US? ▼
What drugs does MARK CALDERWOOD, MD prescribe most often? ▼
Does MARK CALDERWOOD, MD accept Medicare? ▼
How can I verify MARK CALDERWOOD, MD's credentials? ▼
Data Sources
- Provider Directory
- CMS National Plan and Provider Enumeration System (NPPES), download.cms.gov/nppes, updated monthly. Contains NPI, specialty, credentials, and practice location.
- Specialty Classification
- NUCC Health Care Provider Taxonomy (nucc.org), the industry standard for classifying provider specialties in Medicare and Medicaid billing.
- Prescribing Data
- CMS Medicare Part D Prescriber Public Use File (2023). Includes claims, drug costs, beneficiaries, and opioid prescribing rates.
- Limitations
- Provider data is self-reported to CMS. Prescribing data reflects Medicare Part D only and does not include commercial insurance, Medicaid, or cash prescriptions. Claims below 11 beneficiaries are suppressed by CMS for privacy.
See our complete data methodology for details on how we collect and process government data.
Data as of April 2026 (NPPES) / 2023 (Medicare Part D). Source: Centers for Medicare & Medicaid Services (CMS).
Disclaimer: Data from CMS NPPES and Medicare Part D. PlainDoctor does not rate or rank providers. Provider information is self-reported and may not be current. Always verify information directly with the provider. About · Methodology